View Older Stories View More Recent Stories
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
-
Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c
-
Praxis reports positive seizure reduction results from vormatrigine trial
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis receives FDA breakthrough therapy designation for relutrigine
-
Piper Sandler Reiterates OW Rating on Praxis Precision Medicines (PRAX) Post NYC Investor Dinner
-
Oppenheimer Assumes Praxis Precision Medicines Inc. (PRAX) at Outperform
-
Piper Sandler: 'We Remain Bullish on Praxis Precision Medicines Inc. (PRAX)'
-
Chardan Capital Markets Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Praxis Precision Medicines (PRAX) Highlights DEE Clinical Program Updates at Virtual Investor Event
-
Guggenheim on Praxis Precision Medicines Inc. (PRAX): 'remains one of our Top Picks for 2025'
-
Praxis Precision Medicines (PRAX) Misses Q1 EPS by 42c
-
Praxis Precision Medicines (PRAX) announces inducement grants
-
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $61 at TD Cowen
-
Praxis Precision Medicines Inc. (PRAX) PT Lowered to $85 at Truist Securities
-
Praxis Precision Medicines (PRAX) IDMC has recommended Essential3 study be stopped for futility
-
Deutsche Bank Starts Praxis Precision Medicines Inc. (PRAX) at Buy
-
Jefferies Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $175 at Truist; 'Incrementally Positive On Ph3 ESSENTIAL3'
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Praxis Precision Medicines (PRAX) Files Mixed Shelf
-
Piper Sandler on Praxis Precision Medicines Inc. (PRAX): '2025 a Key Year to Drive Substantial Shares Gains'
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $305 at Jefferies
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Guggenheim Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines (PRAX) Misses Q3 EPS by 76c
-
Oppenheimer Reiterates Outperform Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines (PRAX) spreader active in November 65 and 90 calls as share price up 9.6%
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $151 at Needham
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $143 at Oppenheimer
-
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Guggenheim Defending Praxis Precision Medicines Inc. (PRAX): 'we are buyers, especially on the current weakness'
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Truist Securities Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines (PRAX) announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $120 at H.C. Wainwright
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $170 at Guggenheim
-
Oppenheimer Starts Praxis Precision Medicines Inc. (PRAX) at Outperform
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)
-
Piper Sandler Reiterates Overweight Rating on Praxis Precision Medicines Inc. (PRAX)

